Abstract:Medline (MDLN.O) jumps 41% on its Nasdaq debut, sparking strong investor interest. Trade Medline shares easily with FXPro as the stock gains global attention.

Medline (MDLN.O) made a remarkable debut on the Nasdaq, soaring 41% on its first day of trading and setting the pace for what is being hailed as 2025s most successful IPO so far. The companys public market entry underscored strong investor demand for healthcare and industrial leaders, even as broader markets remain uncertain.
The IPO attracted significant attention from institutional and retail investors, driving early gains and solidifying Medlines position as a major player to watch in the year ahead. Analysts note that this performance signals renewed confidence in companies rooted in tangible fundamentals, rather than purely tech-driven valuations.
Founded over five decades ago, Medline is among the worlds leading suppliers of medical and surgical products. Its extensive catalog spans everything from everyday consumables to advanced healthcare equipment, supporting hospitals and clinics worldwide.

In an era dominated by tech IPOs, Medlines strong market reception reaffirms the enduring appeal of resilient, essential industries. Its robust business foundation and consistent demand from the healthcare sector provide a stable outlook for investors seeking long-term value.
FXPro now offers traders access to Medline shares, allowing participation in post-IPO movements as the stock finds equilibrium. Through FXPro, investors can:
FXPro continues to expand its share offerings, adding new listings and major IPOs as they go public. Medlines promising start makes it a compelling addition for traders looking to capitalize on the 2025 IPO wave.
CFDs and Spread Betting are complex instruments and come with a high risk of losing money rapidly due to leverage. 74% of retail investor accounts lose money when trading these products. Please ensure you understand the risks before trading.
FXPro is a leading global broker known for its advanced trading platforms, competitive spreads, and access to a wide range of markets, including stocks, commodities, and major IPOs.


amana, a United Arab Emirates-based broker, is reportedly losing most of the traders’ favour recently. These traders have accused the brokerage entity of serious misconduct, including the long-pending fund withdrawal requests and poor customer services. Negative amana reviews have emerged across broker evaluation platforms such as WikiFX. Through this article, we have covered these allegations while providing our perspective on the broker’s regulatory status. This will help you make an informed call on whether you can trust amana with your capital.

Have you lost a significant amount of capital on the MT.COOK platform? Did you face losses due to wide spreads? Have the overall trading conditions been unpleasant for you as a trader? Did you feel that the platform worked as a Ponzi scheme? You’re not alone! Many traders have accused the brokerage entity of these issues on broker review platforms such as WikiFX. In this MT.COOK review article, we have investigated several complaints. Read on!

HYCM Capital Markets (UK) Limited reported a £236,304 loss for 2025, as higher administrative costs offset a small rise in revenue and reversed the previous year’s profit.

XELLION, a Saint Lucia-based forex broker, is reportedly facing many complaints from users. Among the complaints, the lack of smooth fund withdrawals remains the most disturbing one. This issue was not only highlighted by real users but also the Introducing Broker (IB) who expressed shock over this issue on broker review platforms. In this XELLION review article, we have examined these allegations against the brokerage entity.